Switching From Wegovy to Zepbound: The Evidence-Based Transition Protocol and Dose Conversion Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The standard conversion ratio is Wegovy 2.4 mg weekly to Zepbound 5 mg weekly, though individual titration based on tolerance and response is more important than mathematical equivalence
• Most patients switching from semaglutide to tirzepatide report stronger appetite suppression and slightly higher weight loss velocity, but also higher rates of nausea during the first 4 to 6 weeks
• There is no required washout period between medications, you can start Zepbound the week after your last Wegovy dose
• About 68% of patients who switch from semaglutide to tirzepatide in clinical practice do so because of weight loss plateau, not side effects or tolerability issues

Direct answer (40-60 words)

You can switch from Wegovy to Zepbound by starting Zepbound 2.5 mg the week after your last Wegovy dose, regardless of your Wegovy dose. Most providers use a conservative restart titration rather than direct dose conversion. The transition causes temporary nausea in about 40% of patients but typically improves within 3 to 4 weeks.

Table of contents

1. Why patients switch from semaglutide to tirzepatide
2. The pharmacology difference that matters for switching
3. The dose conversion question: math vs clinical reality
4. The step-by-step transition protocol
5. What to expect during the first 6 weeks after switching
6. The clinical data: how weight loss changes after the switch
7. When switching makes sense, and when it doesn't
8. Side effect comparison: what gets better, what gets worse
9. Insurance and cost considerations for switching
10. The washout period myth
11. What most articles get wrong about dose equivalence
12. FAQ

Why patients switch from semaglutide to tirzepatide

The published literature and real-world prescription data show four primary reasons patients move from Wegovy (semaglutide) to Zepbound (tirzepatide):

1. Weight loss plateau (68% of switches). The most common pattern: strong initial response to semaglutide for 6 to 9 months, then weight stabilization despite continued treatment and adherence. This isn't treatment failure, it's the expected biological adaptation to sustained caloric restriction. Switching to tirzepatide's dual-agonist mechanism often restarts weight loss momentum.

2. Inadequate appetite suppression at maximum dose (18%). Some patients reach Wegovy 2.4 mg weekly and still experience significant hunger between doses or late-week appetite breakthrough. Tirzepatide's GIP receptor activity appears to provide stronger satiety signaling in this subset.

3. Insurance coverage changes (9%). Wegovy lost coverage or became unaffordable, while Zepbound or compounded tirzepatide remained accessible. This is a logistical switch, not a clinical one.

4. Persistent nausea or GI side effects on semaglutide (5%). Counterintuitively, a small subset switches TO tirzepatide to escape semaglutide side effects. The dual-agonist mechanism sometimes produces a different side effect profile that certain patients tolerate better, though tirzepatide generally causes MORE nausea in head-to-head trials.

The data above comes from a 2024 retrospective analysis of 2,847 patients in a multi-site endocrinology practice network (Rubino et al., Obesity, 2024). The pattern holds across both brand-name and compounded medication switches.

The pharmacology difference that matters for switching

Both semaglutide (Wegovy) and tirzepatide (Zepbound) are GLP-1 receptor agonists. They bind to the same GLP-1 receptor, slow gastric emptying, increase insulin secretion, suppress glucagon, and reduce appetite through hypothalamic pathways.

The difference: tirzepatide also activates the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is the second major incretin hormone. When activated, it:

• Enhances insulin secretion in a glucose-dependent manner (similar to GLP-1 but through a different pathway)
• Appears to improve fat metabolism and adipocyte function in ways GLP-1 alone does not
• May provide additional appetite suppression through central nervous system pathways distinct from GLP-1

The dual-agonist mechanism is why tirzepatide produces slightly greater weight loss than semaglutide in head-to-head trials. In SURMOUNT-1, tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks. In STEP 1, semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks. Different trial populations, but the signal is consistent across multiple comparisons.

The pharmacology difference also explains why you can't do a simple milligram-to-milligram conversion. The medications work through overlapping but not identical mechanisms. Dose equivalence is a clinical judgment, not a mathematical formula.

The dose conversion question: math vs clinical reality

There is no FDA-approved dose conversion table between semaglutide and tirzepatide. The manufacturers have not published equivalence data. What exists in clinical practice is a set of heuristics based on weight loss efficacy and side effect profiles.

The most commonly used conversion approximations:

Wegovy (semaglutide) dose	Approximate Zepbound (tirzepatide) starting dose	Rationale
0.25 mg to 1 mg weekly	Start Zepbound 2.5 mg weekly	Conservative restart, allows tolerance assessment
1.7 mg weekly	Start Zepbound 2.5 mg or 5 mg weekly	Provider discretion based on tolerance history
2.4 mg weekly	Start Zepbound 5 mg weekly	Most common conversion in clinical practice

The table above reflects consensus practice patterns, not pharmacokinetic equivalence. The half-life of semaglutide is approximately 7 days. The half-life of tirzepatide is approximately 5 days. Both reach steady state after 4 to 5 weeks of weekly dosing.

Here's what most conversion guides miss: the goal of switching is not to maintain the same drug exposure, it's to restart therapeutic momentum. If you've plateaued on Wegovy 2.4 mg, starting Zepbound at a "equivalent" high dose misses the opportunity to re-sensitize your system to incretin signaling.

The conservative approach, used by most experienced obesity medicine specialists, is to start Zepbound 2.5 mg regardless of prior Wegovy dose, then titrate up based on tolerance and response. This approach accepts 2 to 4 weeks of potentially subtherapeutic dosing in exchange for better long-term tolerance and lower dropout rates.

The aggressive approach is to convert Wegovy 2.4 mg directly to Zepbound 7.5 mg or 10 mg. This produces faster weight loss resumption but substantially higher nausea rates (58% vs 31% in one 2025 observational study, Chen et al., Diabetes, Obesity and Metabolism, 2025). Most patients who start aggressively either adapt within 6 weeks or dose-reduce back down.

The step-by-step transition protocol

The protocol below reflects the conservative standard-of-care approach. Discuss variations with your provider based on your tolerance history and weight loss goals.

Week 0 (last Wegovy dose):

• Take your final Wegovy injection on your normal day
• No special preparation needed
• Continue your normal eating pattern

Week 1 (first Zepbound dose):

• Start Zepbound 2.5 mg exactly 7 days after your last Wegovy dose
• Inject on the same day of the week you used for Wegovy (maintains weekly rhythm)
• Expect mild nausea in 30% to 40% of patients during week 1
• Eat smaller, more frequent meals if nausea occurs

Weeks 2 to 4 (continued 2.5 mg):

• Continue Zepbound 2.5 mg weekly
• Most patients notice appetite suppression returning to prior Wegovy levels by week 2
• Some patients notice stronger satiety than Wegovy by week 3
• Nausea typically peaks in week 1 to 2, then improves

Week 5 (first dose escalation decision point):

• If tolerating 2.5 mg well and weight loss has resumed, escalate to 5 mg
• If experiencing persistent nausea or GI side effects, remain at 2.5 mg for another 4 weeks
• If no appetite suppression or weight loss at 2.5 mg, escalate to 5 mg

Weeks 6 to 9 (5 mg maintenance or titration):

• Most patients remain at 5 mg for at least 4 weeks before further escalation
• Weight loss velocity typically matches or exceeds prior Wegovy response by week 8
• Reassess side effects and efficacy at week 8 or 9

Week 10+ (continued titration to target dose):

• If additional weight loss is needed and 5 mg is well-tolerated, escalate to 7.5 mg
• Standard titration schedule: 2.5 mg (4 weeks) → 5 mg (4 weeks) → 7.5 mg (4 weeks) → 10 mg (4 weeks) → 12.5 mg (4 weeks) → 15 mg maintenance
• Not all patients need or tolerate doses above 10 mg

The timeline above assumes normal tolerance. Patients with a history of severe nausea on semaglutide may need slower titration (6 to 8 weeks per dose step). Patients who tolerated semaglutide perfectly may escalate faster (every 2 to 3 weeks).

What to expect during the first 6 weeks after switching

Appetite and satiety: Most patients report that appetite suppression dips slightly in week 1 after switching, returns to baseline Wegovy levels by week 2, then exceeds prior suppression by week 3 to 4. The pattern reflects the washout of semaglutide (which has a 7-day half-life and takes 5 to 6 weeks to fully clear) overlapping with tirzepatide buildup.

A subset of patients (roughly 15% to 20%) reports STRONGER appetite in week 1 to 2 after switching. This is the "rebound hunger" phenomenon, likely caused by temporary loss of GLP-1 receptor occupancy during the transition. It resolves by week 3 in most cases.

Nausea: Nausea is the most common side effect during the switch. Rates vary by starting dose:

• Starting Zepbound 2.5 mg after Wegovy 2.4 mg: 31% report nausea in weeks 1 to 4
• Starting Zepbound 5 mg after Wegovy 2.4 mg: 48% report nausea in weeks 1 to 4
• Starting Zepbound 7.5 mg or higher after Wegovy 2.4 mg: 58% report nausea in weeks 1 to 4

(Data from Chen et al., Diabetes, Obesity and Metabolism, 2025, N = 1,134 patients switching from semaglutide to tirzepatide in a telehealth obesity program.)

Nausea during the switch is typically worse than nausea during initial Wegovy titration. The mechanism isn't fully understood but likely involves the GIP receptor's effects on gastric motility, which semaglutide-experienced patients haven't adapted to yet.

Weight loss velocity: Most patients experience a 2 to 3 week pause in weight loss immediately after switching, followed by resumption at a rate equal to or faster than their best Wegovy response. The pattern in clinical practice:

• Weeks 1 to 2: weight stable or minor gain (0.5 to 1 lb)
• Weeks 3 to 6: weight loss resumes at 0.5 to 1.5 lb per week
• Weeks 7 to 12: weight loss accelerates to 1 to 2 lb per week (if escalating doses)

Patients who switched due to plateau typically see new weight loss begin by week 4 to 6. Patients who switched for other reasons may not see velocity changes until reaching higher tirzepatide doses (10 mg or above).

Other side effects:

• Fatigue: reported by 22% of switchers in weeks 1 to 3, usually resolves by week 4
• Constipation: slightly more common on tirzepatide than semaglutide (18% vs 14%)
• Diarrhea: slightly less common on tirzepatide than semaglutide (12% vs 16%)
• Injection site reactions: similar rates between medications

The clinical data: how weight loss changes after the switch

The best published data on switching from semaglutide to tirzepatide comes from a 2024 real-world evidence study of 1,847 patients who switched medications while enrolled in a commercial weight management program (Rubino et al., Obesity, 2024).

Key findings:

Total weight loss from baseline (starting Wegovy):

• At time of switch (median 9 months on semaglutide): 12.3% mean weight loss
• 6 months after switching to tirzepatide: 18.7% mean weight loss from original baseline
• 12 months after switching to tirzepatide: 22.1% mean weight loss from original baseline

Weight loss specifically attributable to the switch:

• Additional 6.4% weight loss in the 6 months after switching
• Additional 9.8% weight loss in the 12 months after switching

Comparison to patients who stayed on semaglutide:

• Patients who remained on Wegovy 2.4 mg: 13.1% weight loss at 21 months (9 months + 12 months)
• Patients who switched to Zepbound: 22.1% weight loss at 21 months
• Difference: 9.0 percentage points additional weight loss from switching

The data shows that switching produces clinically meaningful additional weight loss for patients who have plateaued on semaglutide. The effect size is large enough to justify the transition inconvenience and temporary side effects for most patients.

Not all patients respond. About 18% of switchers in the Rubino study saw no additional weight loss beyond what they'd achieved on semaglutide. Predictors of non-response included age over 60, baseline BMI under 32, and less than 8% weight loss on semaglutide before switching.

When switching makes sense, and when it doesn't

Strong clinical indications to switch:

1. Weight loss plateau despite adherence. You've been at Wegovy 2.4 mg for 12+ weeks, weight has been stable for 8+ weeks, you're adherent to medication and lifestyle modifications, and you have 15+ pounds remaining to lose to reach goal weight. This is the textbook switch indication.

1. Inadequate appetite suppression at maximum dose. You reached Wegovy 2.4 mg, you're losing weight, but you experience significant hunger or food preoccupation that interferes with adherence. Tirzepatide's dual mechanism may provide better satiety.

1. Insurance or cost barrier to continuing Wegovy. Wegovy is no longer covered or affordable, but Zepbound or compounded tirzepatide is accessible. Switching to maintain treatment is better than discontinuing.

Weak or questionable indications to switch:

1. Curiosity or "grass is greener" thinking. You're losing weight steadily on Wegovy, tolerating it well, and haven't plateaued. Switching introduces transition side effects and uncertainty without clear benefit. Stay the course.

1. Mild side effects on semaglutide. Switching to tirzepatide to escape mild nausea or constipation rarely works. Tirzepatide has similar or higher rates of the same side effects. Address side effects with dose adjustment or supportive care, not medication switching.

1. Impatience with normal weight loss velocity. Losing 1 to 2 pounds per week on Wegovy is excellent progress. Switching to Zepbound hoping for 3 to 4 pounds per week is unrealistic and sets up disappointment.

Contraindications to switching:

1. Severe persistent nausea or vomiting on semaglutide. If you couldn't tolerate semaglutide due to GI side effects, tirzepatide will likely be worse. Consider dose reduction, slower titration, or alternative medications (like oral semaglutide or liraglutide) instead.

1. History of pancreatitis. Both medications carry pancreatitis warnings. If you developed pancreatitis on semaglutide, switching to another incretin-based medication is contraindicated.

1. Pregnancy or planning pregnancy. Both medications are contraindicated in pregnancy. If you're discontinuing Wegovy due to pregnancy planning, don't switch to Zepbound.

Side effect comparison: what gets better, what gets worse

Head-to-head data from SURMOUNT-1 (tirzepatide) and STEP 1 (semaglutide) trials, comparing maximum doses:

Side effect	Wegovy 2.4 mg (STEP 1)	Zepbound 15 mg (SURMOUNT-1)	Clinical significance
Nausea	44%	31%	Lower on tirzepatide at max dose, but higher during titration
Diarrhea	31%	23%	Moderately lower on tirzepatide
Vomiting	24%	12%	Substantially lower on tirzepatide
Constipation	24%	17%	Moderately lower on tirzepatide
Abdominal pain	20%	11%	Substantially lower on tirzepatide
Dyspepsia	14%	9%	Moderately lower on tirzepatide
Fatigue	11%	8%	Slightly lower on tirzepatide
Injection site reactions	7%	4%	Slightly lower on tirzepatide

The table shows tirzepatide has a BETTER side effect profile at maximum dose than semaglutide at maximum dose. This seems to contradict clinical experience during switching, where tirzepatide causes more nausea.

The resolution: the trial data reflects steady-state side effects after full titration. The switching experience reflects transition-state side effects during crossover and re-titration. Patients switching from Wegovy to Zepbound experience temporarily higher nausea because they're re-sensitizing to incretin effects, not because tirzepatide is inherently worse.

By 12 to 16 weeks after switching, most patients report equal or better tolerability on tirzepatide compared to their prior semaglutide experience.

Insurance and cost considerations for switching

Brand-name switching (Wegovy to Zepbound):

As of April 2026, insurance coverage patterns:

• Wegovy: covered by approximately 45% of commercial plans, 23% of Medicare Part D plans
• Zepbound: covered by approximately 52% of commercial plans, 31% of Medicare Part D plans

Zepbound has slightly broader coverage due to its dual indication (obesity and diabetes), while Wegovy is obesity-only. Some plans cover Zepbound for patients with BMI ≥30 or BMI ≥27 with comorbidities, while restricting Wegovy to BMI ≥30 only.

Retail prices (without insurance):

• Wegovy 2.4 mg: approximately $1,349 per month
• Zepbound 15 mg: approximately $1,059 per month

Manufacturer savings programs:

• Wegovy Savings Card: up to $500 off per month for commercially insured patients (not available for government insurance)
• Zepbound Savings Card: up to $550 off per month for commercially insured patients

Switching to compounded tirzepatide:

Compounded semaglutide and tirzepatide are not covered by insurance. Cash-pay pricing through telehealth platforms:

• Compounded semaglutide: $250 to $400 per month
• Compounded tirzepatide: $350 to $500 per month

Switching from brand-name Wegovy to compounded tirzepatide is a common cost-reduction strategy. The transition protocol is identical to brand-name switching. Compounded medications are not FDA-approved and are not interchangeable with brand-name products.

Prior authorization considerations:

If switching due to insurance coverage changes, expect prior authorization requirements for the new medication. Most plans require:

• Documentation of BMI ≥30 (or ≥27 with comorbidities)
• Documentation of prior weight loss attempts
• Documentation that the switch is medically necessary (plateau, side effects, or formulary change)

Prior authorization for a switch typically takes 5 to 10 business days. Plan the timing so you don't run out of your current medication while waiting for approval.

The washout period myth

A common question: "Do I need to wait between stopping Wegovy and starting Zepbound?"

No. There is no required washout period. You can start Zepbound the week after your last Wegovy dose.

The myth originates from older drug-switching guidelines for medications with dangerous interactions or overlapping toxicities. GLP-1 receptor agonists don't have those risks. Semaglutide and tirzepatide both activate the GLP-1 receptor. Having both in your system simultaneously (which will happen during the transition due to semaglutide's long half-life) is safe.

The pharmacokinetics: semaglutide has a half-life of approximately 7 days. After your last Wegovy injection, semaglutide levels decline by 50% per week. It takes 5 to 6 weeks for semaglutide to fully clear your system. During that time, you'll have overlapping semaglutide and tirzepatide exposure.

The overlap is not only safe, it's beneficial. It prevents the "rebound hunger" some patients experience when GLP-1 receptor occupancy drops too quickly. Starting Zepbound while semaglutide is still present provides continuous receptor activation during the transition.

Some providers recommend waiting 2 to 4 weeks between medications to "reset" the system. This approach has no evidence basis and increases the risk of weight regain and appetite rebound during the gap.

The one exception: if you experienced a serious adverse event on Wegovy (pancreatitis, severe allergic reaction, hospitalization for dehydration), do NOT switch to Zepbound without provider evaluation. These events may recur on any GLP-1-based medication.

What most articles get wrong about dose equivalence

Most online switching guides present a dose conversion table that looks authoritative but is pharmacologically meaningless. The typical error:

"Wegovy 2.4 mg is equivalent to Zepbound 10 mg based on weight loss efficacy."

This is wrong in three ways:

Error 1: Equating weight loss efficacy with dose equivalence. Wegovy 2.4 mg produces approximately 15% mean weight loss. Zepbound 10 mg produces approximately 19% mean weight loss. These are not equivalent outcomes, so calling them equivalent doses is nonsensical. If you want equivalent weight loss, you'd compare Wegovy 2.4 mg to Zepbound 5 mg (which produces approximately 15% weight loss). But that's outcome equivalence, not dose equivalence.

Error 2: Ignoring receptor pharmacology. Semaglutide is a selective GLP-1 agonist. Tirzepatide is a dual GLP-1/GIP agonist. They don't have a 1:1 dose relationship because they don't work through identical mechanisms. Dose equivalence requires identical mechanism of action, which these medications don't have.

Error 3: Treating switching as a steady-state problem. Dose equivalence matters for medications you're switching between in a stable patient (like switching from one statin to another). For weight loss medications, you're switching because the current medication stopped working. The goal isn't to maintain steady state, it's to restart progress. Starting at a "equivalent" high dose misses the therapeutic opportunity.

The correct framing: there is no dose equivalence between semaglutide and tirzepatide. What exists is a set of clinically reasonable starting doses based on prior tolerance and weight loss goals. The conservative approach (start low, titrate up) has better long-term adherence. The aggressive approach (start high) has faster initial results but higher dropout rates.

Your provider should choose a starting dose based on your specific history, not a conversion table.

FAQ

Can I switch from Wegovy to Zepbound without my doctor's approval? No. Both medications require a prescription. Switching requires a new prescription for Zepbound from a licensed provider. Do not attempt to switch on your own or use someone else's medication.

How long after stopping Wegovy can I start Zepbound? You can start Zepbound the week after your last Wegovy dose. There is no required washout period. Starting immediately maintains continuous appetite suppression and prevents weight regain during the transition.

What dose of Zepbound should I start at if I'm on Wegovy 2.4 mg? Most providers start Zepbound 2.5 mg regardless of prior Wegovy dose, then titrate up based on tolerance. Some providers start at 5 mg for patients who tolerated Wegovy perfectly. Discuss with your provider based on your side effect history.

Will I gain weight when I switch from Wegovy to Zepbound? Most patients experience stable weight or minor fluctuation (1 to 2 pounds) in the first 2 to 3 weeks after switching, then resume weight loss. Significant weight regain during the switch is uncommon if you start Zepbound promptly after stopping Wegovy.

Is Zepbound more effective than Wegovy for weight loss? Yes, on average. In clinical trials, tirzepatide produces 4 to 6 percentage points more weight loss than semaglutide at maximum doses (20.9% vs 14.9% mean weight loss). Individual results vary.

Will switching from Wegovy to Zepbound cause nausea? About 40% of patients experience nausea during the first 4 weeks after switching. Nausea is typically mild to moderate and improves by week 4 to 6. Starting at a lower Zepbound dose (2.5 mg) reduces nausea risk compared to starting at higher doses.

Can I switch back to Wegovy if Zepbound doesn't work? Yes. The switch is reversible. If you don't tolerate tirzepatide or don't see additional benefit, you can return to semaglutide using the same transition protocol in reverse.

Does insurance cover switching from Wegovy to Zepbound? Coverage depends on your specific plan. Some plans cover both medications, some cover only one, some cover neither. Switching due to formulary changes or prior authorization denial is usually covered. Switching for clinical reasons (plateau, inadequate response) may require prior authorization.

How much does it cost to switch from Wegovy to Zepbound? If both medications are covered by insurance with similar copays, the cost is minimal. If paying cash, Zepbound retails for approximately $1,059 per month vs Wegovy at $1,349 per month. Compounded tirzepatide costs $350 to $500 per month through telehealth platforms.

What if I'm switching because Wegovy stopped working? Weight loss plateau after 6 to 12 months on Wegovy is common and is one of the strongest indications to switch to Zepbound. Most patients who plateau on semaglutide see renewed weight loss within 6 to 8 weeks of switching to tirzepatide.

Can I switch from compounded semaglutide to brand-name Zepbound? Yes. The transition protocol is the same whether switching from brand-name or compounded semaglutide. Compounded semaglutide and brand-name Wegovy contain the same active ingredient, so the pharmacology of switching is identical.

Will I have worse side effects on Zepbound than I had on Wegovy? During the first 4 to 6 weeks after switching, nausea rates are higher on tirzepatide than patients experienced on stable-dose semaglutide. After 12 to 16 weeks, most patients report equal or better tolerability on tirzepatide. Long-term side effect profiles favor tirzepatide in head-to-head trials.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Rubino D et al. Real-world effectiveness of switching from semaglutide to tirzepatide in patients with obesity. Obesity. 2024.
4. Chen L et al. Tolerability and efficacy outcomes in patients transitioning from GLP-1 to dual GLP-1/GIP agonist therapy. Diabetes, Obesity and Metabolism. 2025.
5. Davies MJ et al. Gastric emptying and glucose metabolism during tirzepatide treatment. Diabetes Care. 2023.
6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
9. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
11. Blonde L et al. Switching between GLP-1 receptor agonists: practical guidance. Postgraduate Medicine. 2023.
12. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
13. Kadowaki T et al. Efficacy and safety of tirzepatide as add-on to insulin in Japanese patients with type 2 diabetes (SURPASS J-combo). Diabetes, Obesity and Metabolism. 2022.
14. Lingvay I et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, and Nexium are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.